<< Young, male, and infected - the forgotten victims of Chlamydia | Doctors under pressure to compromise good health care for athletes >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Basis for deciding cost effectiveness of TB vaccination programmes questioned

Published on January 26, 2005 at 6:35 PM · No Comments

Current risk assessment methods, which are used to inform the timing and extent of tuberculosis (TB) vaccination programmes, may overestimate the real risk of contracting the disease up to threefold, reveals research in Thorax.Current risk assessment methods, which are used to inform the timing and extent of tuberculosis (TB) vaccination programmes, may overestimate the real risk of contracting the disease up to threefold, reveals research in <<>>.

The findings have prompted a leading expert to question the validity of the ways in which decisions are made as to whether TB vaccination programmes, such as those offered to 13 and 14 year olds in the UK, are cost effective

Researchers analysed the results of tuberculin skin tests in 21,000 children aged between 6 and 9 years in Hong Kong, where all newborn babies are routinely vaccinated against TB.

Tuberculin tests use injectable TB antigens to assess whether a person has ever been exposed to the bacteria that cause the infection, based on the extent of the ensuing skin reaction. They cannot, however, measure how long a person has been infected, or whether the infection is active, and can therefore be passed on to others.

The results were fed into three different approaches in a bid to estimate the subsequent annual risk of TB infection.

The first approach relied on the extent of the skin reaction and the age of the child; the second approach compared positive test results in two age groups?6 to 7 year olds and 8 to 9 year olds; and the third concentrated on the size of the skin reaction, referred to as the "secondary peak."

The first and second approaches are routinely used to calculate the probable cost effectiveness of mass TB vaccination programmes.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading